Supplementary table 1: List of antineoplastic agents included in the current analysis.

|  |  |
| --- | --- |
| Category  | List of agents included in the study |
| Anthracyclines | Doxorubicin; Epirubicin |
| Topoisomerase inhibitors | Etoposide, irinotecan, topotecan |
| Taxanes | Paclitaxel; docetaxel  |
| Vinca alkaloids | vincristine, vinblastine |
| Platinum agents | Cisplatin, carboplatin, oxaliplatin |
| Alkylating agents | Cyclophosphamide, ifosfamide, temozolomide, dacarbazine, lomustine, melphalan |
| Antimetabolites  | Fluorouracil, capecitabine, gemcitabine, pemetrexed |
| Hormonal agents (including CDK inhibitors/ PARP inhibitors) | Tamoxifen, letrozole, exemestane, anastrazolePalbocicilib, ribocicilib, abemaciclibOlaparib, niraparib |
| Monoclonal antibodies | Bevacizumab, ramucirumabCetuximab, panitumumabTrastuzumab, pertuzumab |
| Tyrosine kinase inhibitors | VEGFR-TKI: sorafenib, sunitinib, EGFR-TKI: erlotinib, gefitinib, afatinib, osimertinibALK-TKI: Crizotinib, alectinib, lorlatinib, brigatinib, ceritinib |
| Immune checkpoint inhibitors | Nivolumab, pembrolizumab, atezolizumab, durvalumab and avelumab |

Supplementary table-2: Pregnancy outcomes for selected single agents (with > 90 reports):

|  |  |  |  |
| --- | --- | --- | --- |
| Outcomes | Cyclophosphamide (240 reports) | Rituximab (94 reports) | Trastuzumab (196 reports) |
| N (%) | N (%) | N (%) |
| Abortion | 22 (9.2) | 13 (13.8) | 36 (18.4) |
| Still birth  | 7 (2.9) | 0 | 1 (0.5) |
| Ectopic pregnancy | 0 | 0 | 3 (1.5) |
| Premature delivery | 32 (13.3) | 7 (7.4) | 27 (13.8) |
| Premature rupture of the membranes | 2 (0.8) | 0 | 3 (1.5) |
| Eclampsia/ pre-eclampsia | 0 | 1 (1.1) | 1 (0.5) |
| Oligo/polyhydramnios | 0 | 0 | 40 (20.4) |
| Postpartum hemorrhage | 0 | 0 | 0 |

Supplementary table-3: Fetal outcomes for selected single agents (with > 90 reports):

|  |  |  |  |
| --- | --- | --- | --- |
| Outcomes | Cyclophosphamide (240 reports) | Rituximab (94 reports) | Trastuzumab (196 reports) |
| N (%) | N (%) | N (%) |
| Fetal/ neonatal death/ stillbirth | 30 (12.5) | 15 (16) | 41 (20.9) |
| Abnormal cytogenetics | 0 | 2 (2.1) | 2 (1) |
| Fetal growth restriction/ small for dates/ low birth weight | 3 (1.3) | 4 (4.3) | 6 (3.1) |
| Neonatal disorders\* | 0 | 1 (1.1) | 2 (1) |
| Fetal distress syndrome, neonatal respiratory distress, transient tachypnea of the newborn  | 2 (0.8) | 2 (2.1) | 4 (2) |
| Congenital malformations | 3 (1.3) | 12 (12.8) | 14 (7.1) |
| Autism/ developmental disorders | 1 (0.4) | 0 | 0 |